ProMIS Neurosciences Exceeds Enrollment in Alzheimer's Trial, Eyes Interim Data
Event summary
- ProMIS Neurosciences completed enrollment of 144 patients in its Phase 1b PRECISE-AD clinical trial for PMN310, exceeding the initial target of 128.
- The trial, designed to assess safety, tolerability, and biomarker effects, is expected to yield blinded 6-month interim data in Q2 2026 and final results in Q4 2026.
- PMN310 is designed to selectively target toxic amyloid-beta oligomers, aiming to reduce the risk of amyloid-related imaging abnormalities (ARIA).
- The company received Fast Track designation from the FDA in July 2025 for PMN310.
The big picture
The Alzheimer’s drug development space remains highly competitive, with a history of clinical trial failures and significant regulatory hurdles. ProMIS Neurosciences' approach, targeting toxic oligomers rather than plaques, represents a potential differentiation strategy, but the PRECISE-AD trial results will be pivotal in validating this hypothesis. The over-enrollment suggests investor and patient enthusiasm, but also increases the statistical burden for demonstrating efficacy.
What we're watching
- Efficacy Signals
- The Q2 2026 interim data release will be critical; a lack of discernible biomarker changes could significantly undermine the therapeutic hypothesis and investor confidence.
- ARIA Risk
- The trial's design emphasizes minimizing ARIA, a common side effect of amyloid-targeting therapies; the incidence of ARIA in the Phase 1b trial will be a key indicator of PMN310's differentiated safety profile.
- Competitive Landscape
- The success of PMN310, and its ability to demonstrate a favorable safety and efficacy profile, will be weighed against the progress of other amyloid-targeting therapies in development, potentially influencing market share and pricing dynamics.
Related topics